TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21124330
Drug: Benidipine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine (2 mg/day increased to 8 mg/day)
Study: 20649501
Drug: Cilnidipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine (5 mg/day increased to 20 mg/day)
Study: 17704024
Drug: Low lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lactose infant formula supplemented with added precooked rice (1.5 g/100mL) with probiotic, prebiotic, fiber and increased amounts of zinc+iron
Study: 17704024
Drug: Low lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lactose infant formula with added precooked rice without the above active ingredient supplement
Study: 15846251
Drug: GRD 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 180 mg evening dose
Study: 15846251
Drug: GRD 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 360 mg evening dose
Study: 15846251
Drug: GRD 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 360 mg morning dose
Study: 15846251
Drug: GRD 420
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 420 mg evening dose
Study: 15846251
Drug: GRD 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRD 360 mg evening dose vs GRD 360 mg morning dose
Study: 15846251
Drug: All GRD
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All GRD doses
Study: 3645177
Drug: Educational sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational sessions designed to teach students various aspects of oral health
Study: 3645177
Drug: Oral examination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral examination control (Group one)
Study: 2551359
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (CVM for 6 cycles)
Study: 2551359
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (NM)
Study: 2551359
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (CVM for 6 cycles) among patients in complete remission
Study: 2551359
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (NM) among patients in complete remission
Study: 31752508
Drug: Interpersonal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal and social rhythm therapy (IPSRT) with cognitive remediation
Study: 28701300
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion to the ileum (15 g, 235 kJ)
Study: 28701300
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion to the duodenum (15 g, 235 kJ)
Study: 28701300
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion to the ileum
Study: 28701300
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion to the duodenum
Study: 17993283
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg/day, 35 mg/week, 50 mg/week, 15 mg/day)
Study: 8518603
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug withdrawal
Study: 8518603
Drug: Continued antiepileptic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued antiepileptic drug treatment
Study: 31096264
Drug: THC (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (one pill, administered 2 hours before threat extinction learning)
Study: 31096264
Drug: Placebo (PBO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO, administered 2 hours before threat extinction learning)
Study: 25950418
Drug: Daily oropharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oropharyngeal exercises
Study: 12852841
Drug: Loratadine (LOR)
Normalized name: Loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loratadine (LOR) 20 mg
Study: 9141231
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg atenolol per day (beta-blocker group)
Study: 9141231
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fosinopril per day alone (control group)
Study: 7506156
Drug: Nimesulide 100mg
Normalized name: nimesulide 100 MG
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100mg twice daily for three 10-day cycles
Study: 7506156
Drug: Nimesulide 200mg
Normalized name: nimesulide 200 MG
DrugBank: Nimesulide (DB04743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200mg twice daily via rectal route
Study: 7506156
Drug: Ketoprofen 100mg
Normalized name: KETOPROFEN 100MG CAP,SA
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 100mg twice daily via rectal route
Study: 2962418
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg 17 beta‐estradiol cyclo‐octyl acetate (E2COA) and 0.15 mg desogestrel for 21 days, followed by 0.03 mg desogestrel for an additional 7 days in half the group
Study: 2962418
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg desogestrel added during the fourth investigation week
Study: 18492834
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (5 mL/d, mean intake 3.1 g/d (n‐3) LCPUFA)
Study: 14578244
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (0.5 units/kg s.c.)
Study: 14578244
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (0.5 IU/kg)
Study: 8817416
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose radiotherapy with chemotherapy
Study: 1386691
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation (causing a nearly 20% fall in FEV1)
Study: 6405435
Drug: d‐Amp (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐Amp (10 mg)
Study: 6405435
Drug: d‐Amp (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐Amp (20 mg)
Study: 15297952
Drug: Foot and
Normalized name: Carrington Foot and Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot and hand massage (20 minutes, 5 minutes to each extremity) provided 1 to 4 hours after pain medication
Study: 9566646
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg day[-1])
Study: 9566646
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg day[-1]) + omega-3 fatty acids (4 g day[-1])
Study: 9566646
Drug: omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 fatty acids (4 g day[-1])
Study: 9360002
Drug: Lisinopril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20 mg once a day)
Study: 2037324
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine administered intrapleurally
Study: 24631095
Drug: JE-CV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV and MMR vaccines administered concomitantly (Group 'Co-Ad')
Study: 24631095
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine administered separately after JE-CV (Group 'MMR')
Study: 24631095
Drug: JE-CV vaccine
Normalized name: Japanese encephalitis virus vaccine Nakayama-NIH strain, inactivated Injectable Suspension [Je-Vax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV vaccine administered separately before MMR (Group 'JE-CV')
Study: 24631095
Drug: JE-CV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: JE-CV and MMR vaccines administered separately 6 weeks apart (Groups 'JE-CV' and 'MMR')
Study: 22691917
Drug: IV-administered acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-administered acetaminophen 30 mg/kg, administered at the end of surgery and thereafter twice at 8-hour intervals
Study: 22691917
Drug: IV-administered acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV-administered acetaminophen 30 mg/kg
Study: 19585478
Drug: Spearmint tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spearmint tea (twice a day for 30 days)
Study: 9767554
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg daily of oral, micronized estradiol
Study: 30927124
Drug: Hemospray (TC-325)
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemospray (TC-325) with epinephrine injection
Study: 30927124
Drug: Hemoclip with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoclip with epinephrine injection
Study: 22210362
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy for 1 hour
Study: 20810251
Drug: Drug increase
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug increase
Study: 20810251
Drug: Drug interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug interventions identified by epileptologists
Study: 15964564
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg, n=16)
Study: 10482259
Drug: Campath‐1H monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Campath‐1H monoclonal antibody treatment
Study: 8760782
Drug: Mometasone furoate,
Normalized name: Mometasone Furoate, 50 mcg/inh nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate, 200 micrograms once daily
Study: 8760782
Drug: Beclomethasone dipropionate,
Normalized name: Beclomethasone Dipropionate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate, 200 micrograms twice daily (400 micrograms total dose)
Study: 31384292
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (pain management, bronchodilator inhalers, oxygen support, mechanical ventilation if needed, pulmonary physical therapy)
Study: 25683094
Drug: Oral salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral salt supplementation (113 mmol Na(+) and 112 mmol Cl(‐))
Study: 25683094
Drug: Oral salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral salt supplementation
Study: 23070151
Drug: IDX184 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 25 mg once daily for 3 days
Study: 23070151
Drug: IDX184 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 50 mg once daily for 3 days
Study: 23070151
Drug: IDX184 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 75 mg once daily for 3 days
Study: 23070151
Drug: IDX184 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDX184 100 mg once daily for 3 days
Study: 17961729
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with autologous hematopoietic stem cell support (AHSCT)
Study: 15674510
Drug: Landiolol 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 5 mg
Study: 15674510
Drug: Landiolol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol 10 mg
Study: 2227553
Drug: Chemotherapy (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (3 additional courses)
Study: 28087382
Drug: Egg rush
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg rush oral immunotherapy (ROIT) in ROIT1 group
Study: 28087382
Drug: Egg rush
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg rush oral immunotherapy (ROIT) in ROIT2 group
Study: 26043229
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype (common allele)
Study: 23311856
Drug: Usual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual and Customary Therapy of Equivalent Dose (DEUCC)
Study: 23311856
Drug: Usual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual and Customary Therapy (UCC)
Study: 9060567
Drug: Sucralfate solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate solution, used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores.
Study: 9060567
Drug: Placebo solution,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution, used four times daily for 7 days starting on the first day of mouth tenderness or mouth sores.
Study: 2868162
Drug: tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamoxifen 20 mg daily
Study: 26476022
Drug: IV tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tPA + endovascular therapy (Solitaire stent-retriever)
Study: 19672742
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group II (oral compound calcium acid chelate, Vitamin AD guttate and ipriflavone)
Study: 19672742
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group I (oral compound calcium acid chelate and Vitamin AD guttate)
Study: 19672742
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo and compound calcium acid chelate)
Study: 18782465
Drug: Simvastatin monotherapy
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin monotherapy (n = 229)
Study: 16184721
Drug: Octreotide 0.1
Normalized name: octreotide 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 0.1 mg subcutaneously 3 times/day for 7 days
Study: 8927315
Drug: Ciba Vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciba Vision AOSept Disinfection/Neutralization Solutions (AOSept)
Study: 8927315
Drug: Opti‐Free Rinsing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opti‐Free Rinsing, Disinfection, and Storage Solution (Opti‐Free)
Study: 8927315
Drug: ReNu Multi‐Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReNu Multi‐Purpose Solution (ReNu)
Study: 6328637
Drug: Cimetidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1 g daily in divided doses)
Study: 31793630
Drug: Adalimumab combination
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab combination therapy (34 patients)
Study: 31793630
Drug: Adalimumab monotherapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab monotherapy (44 patients)
Study: 31793630
Drug: Adalimumab combination
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab combination therapy and monotherapy
Study: 29056106
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary calcium (547 mg DC)
Study: 29056106
Drug: High supplemental
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High supplemental calcium (500 mg SC-calcium carbonate)
Study: 29056106
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium (42 mg DC)
Study: 9630386
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (0.9 g total catechins)
Study: 9630386
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (0.3 g total catechins)
Study: 9630386
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea with milk (100 ml in 600 ml)
Study: 3135784
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) at 120% of resting energy expenditure (REE) with 0.2 g of N/kg/d
Study: 3135784
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) at 200% of resting energy expenditure (REE) with 0.33 g of N/kg/d
Study: 31394274
Drug: Flu-based conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu-based conditioning (Flu1: Flu 120-150 mg/m2, Cy 120-200 mg/kg, ATG 20 mg/kg; Flu2: Flu 150 mg/m2, Cy 300 mg/m2, ATG 20 mg/kg)
Study: 25050594
Drug: BDP/F‐HFA 100/6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/F‐HFA 100/6 μg pMDI
Study: 25050594
Drug: Budesonide/formoterol 320/9 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol 320/9 μg DPI
Study: 25050594
Drug: Fluticasone/salmeterol 500/50 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone/salmeterol 500/50 μg DPI
Study: 19228428
Drug: Prednisolone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (30 mg once daily) plus inhaled formoterol (9 microg bid)
Study: 16402915
Drug: Milrinone (n=15)
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone (n=15) infusion for 72 hours
Study: 16402915
Drug: Dobutamine (n=14)
DrugBank: Dobutamine (DB00841)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dobutamine (n=14) infusion for 72 hours
Study: 16402915
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with decompensated CHF before inotropic treatment
Study: 8702068
Drug: Bionator treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionator treatment for an average of 18.7 months
Study: 1233531
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage of perphenacine
Study: 25443473
Drug: Treatment Burden
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Burden scale
Study: 23136195
Drug: Rilotumumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (15 mg/kg) plus mitoxantrone and prednisone (MP)
Study: 23136195
Drug: Rilotumumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (7.5 mg/kg) plus mitoxantrone and prednisone (MP)
Study: 23136195
Drug: Rilotumumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (15 mg/kg) and (7.5 mg/kg)
Study: 16908789
Drug: Varenicline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 1.0 mg twice daily
Study: 16908789
Drug: Varenicline 0.5
Normalized name: varenicline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline 0.5 mg twice daily
Study: 16908789
Drug: Varenicline (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (both doses)
Study: 11759177
Drug: Phospholipid liposomes
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid liposomes (Liposom Forte) administered intramuscularly (2 ml every other day for 60 days)
Study: 11759177
Drug: Phospholipid liposomes
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid liposomes (Liposom Forte) administered intramuscularly
Study: 9160017
Drug: Factors other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factors other than treatment
Study: 8195354
Drug: Superovulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superovulation with pure follicle stimulating hormone (FSH)
Study: 3073903
Drug: Monocomponent human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monocomponent human insulin
Study: 16458316
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day niacin
Study: 11123486
Drug: Baclofen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (40 mg maximum daily dose, given three times a day)
Study: 11123486
Drug: Clonidine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.8 mg maximum daily dose, given three times a day)
Study: 9387732
Drug: Injection Salviae
Normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Salviae Miltiorrhizae
Study: 1329919
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg
Study: 1329920
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 7500 I.U.
Study: 1329920
Drug: Both Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Enoxaparin and UF heparin
Study: 23980693
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of sedatives (stopped daily and restarted when COMFORT-behavior score ≥17)
Study: 23980693
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of sedatives
Study: 18029971
Drug: Chemotherapy (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (5-FU and adriamycin)
Study: 16294263
Drug: Risedronate 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 2.5 or 5 mg daily for up to 3 years
Study: 12131600
Drug: Venlafaxine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (maximum of 150 mg/day)
Study: 2947149
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg, three tablets daily for two weeks)
Study: 2947149
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three tablets daily for two weeks)
Study: 29482596
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Haloperidol and Ketamine
Study: 10905596
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (3 MU/thrice weekly of alpha-IFN and 1000-1200 mg/daily of ribavirin)